Komipharm International Co. Ltd (041960) - Total Liabilities
Based on the latest financial reports, Komipharm International Co. Ltd (041960) has total liabilities worth ₩61.86 Billion KRW (≈ $41.92 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Komipharm International Co. Ltd (041960) equity growth momentum to track the company's year-over-year net asset growth rate.
Komipharm International Co. Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Komipharm International Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See Komipharm International Co. Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Komipharm International Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Komipharm International Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Legato Merger Corp. III
NYSE MKT:LEGT
|
USA | $7.04 Million |
|
Palram
TA:PLRM
|
Israel | ILA541.94 Million |
|
TianJin JinRong TianYu Precision Machinery Inc.
SHE:300988
|
China | CN¥1.01 Billion |
|
Jiangsu Sainty Corp Ltd
SHG:600287
|
China | CN¥626.84 Million |
|
Shanghai Kaichuang Marine International Co Ltd
SHG:600097
|
China | CN¥1.05 Billion |
|
MM Forgings Limited
NSE:MMFL
|
India | Rs15.56 Billion |
|
Taeyoung Engineering & Construction Co.,Ltd.
KO:009415
|
Korea | ₩3.15 Trillion |
|
Federal-Mogul Goetze (India) Limited.
NSE:FMGOETZE
|
India | Rs4.95 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Komipharm International Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 041960 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Komipharm International Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Komipharm International Co. Ltd (2011–2025)
The table below shows the annual total liabilities of Komipharm International Co. Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩61.86 Billion ≈ $41.92 Million |
+8.09% |
| 2024-12-31 | ₩57.23 Billion ≈ $38.78 Million |
-2.31% |
| 2023-12-31 | ₩58.58 Billion ≈ $39.70 Million |
+14.60% |
| 2022-12-31 | ₩51.12 Billion ≈ $34.64 Million |
+4.75% |
| 2021-12-31 | ₩48.80 Billion ≈ $33.07 Million |
+6.93% |
| 2020-12-31 | ₩45.64 Billion ≈ $30.93 Million |
-12.85% |
| 2019-12-31 | ₩52.37 Billion ≈ $35.49 Million |
+12.58% |
| 2018-12-31 | ₩46.52 Billion ≈ $31.52 Million |
-3.09% |
| 2017-12-31 | ₩48.00 Billion ≈ $32.53 Million |
-15.26% |
| 2016-12-31 | ₩56.64 Billion ≈ $38.38 Million |
-1.08% |
| 2015-12-31 | ₩57.26 Billion ≈ $38.80 Million |
-19.62% |
| 2014-12-31 | ₩71.24 Billion ≈ $48.28 Million |
+11.18% |
| 2013-12-31 | ₩64.08 Billion ≈ $43.42 Million |
+75.98% |
| 2012-12-31 | ₩36.41 Billion ≈ $24.68 Million |
+46.34% |
| 2011-12-31 | ₩24.88 Billion ≈ $16.86 Million |
-- |
About Komipharm International Co. Ltd
Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis se… Read more